Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study
暂无分享,去创建一个
Y. Okabe | M. Shimokawa | T. Otsuka | K. Mitsugi | S. Arima | T. Mizuta | T. Shirakawa | T. Honda | A. Komori | K. Nio | Hiroki Taguchi | A. Makiyama | M. Fukahori | F. Koga | N. Ureshino | Y. Ide | Y. Ueda | S. Otsu | T. Shibuki | J. Nakazawa
[1] Y. Okabe,et al. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study , 2021, International Journal of Clinical Oncology.
[2] M. Fredrikson,et al. Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer , 2020, Frontiers in Oncology.
[3] Wu-Hu Zhang,et al. Haemoglobin, albumin, lymphocyte and platelet predicts postoperative survival in pancreatic cancer , 2020, World journal of gastroenterology.
[4] J. Furuse,et al. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines , 2020, Journal of Gastroenterology.
[5] C. Lu,et al. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second‐line palliative chemotherapy , 2019, Journal of gastroenterology and hepatology.
[6] S. Hayami,et al. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer. , 2019, Surgery.
[7] D. V. Von Hoff,et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. , 2019, European journal of cancer.
[8] Joon-Oh Park,et al. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). , 2019, European journal of cancer.
[9] Zhiqiang Sun,et al. Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real‐world study , 2018, Cancer medicine.
[10] Zhaoshen Li,et al. Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma , 2017, Scientific Reports.
[11] M. Malafa,et al. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. , 2016, Surgery.
[12] Y. Ku,et al. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios , 2016, Surgery Today.
[13] A. Carrato,et al. A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs , 2015, Journal of Gastrointestinal Cancer.
[14] Ben Tran,et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.
[15] B. Dörken,et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.
[16] U. Mansmann,et al. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer , 2010, Tumor Biology.
[17] F. Gay,et al. Prognostic Factors and Prognostic Index for Chemonaïve and Gemcitabine-Refractory Patients with Advanced Pancreatic Cancer , 2008, Oncology.